Literature DB >> 12584341

As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity.

Lionel Berthoux1, Greg J Towers, Cagan Gurer, Paolo Salomoni, Pier Paolo Pandolfi, Jeremy Luban.   

Abstract

Potent drugs such as cyclosporine have provided effective probes of signal transduction pathways and, as well, of human immunodeficiency virus type 1 (HIV-1) replication mechanisms. Recently, it was reported that As(2)O(3), a drug used to treat acute promyelocytic leukemia (PML), stimulates HIV-1 replication. We found that As(2)O(3) accelerates the kinetics of a spreading HIV-1 infection in human T cells and increases the number of cells bearing HIV-1 provirus after a single round of infection. The stimulatory effect occurred after membrane fusion and resulted in increased steady-state levels of newly synthesized viral cDNA. Stimulation was independent of HIV-1 env and most viral accessory genes, and As(2)O(3) had no detectable effects on viral expression postintegration or virion assembly. Murine leukemia virus (MLV) transduction was enhanced by As(2)O(3) to the same extent as HIV-1 transduction, but As(2)O(3) had no additional effect on Fv1 restriction. In contrast, As(2)O(3) largely overcame the specific block to N-tropic MLV reverse transcription posed by human Ref1. As(2)O(3) disrupts PML bodies, nuclear structures named for a major component, the PML protein. We observed no changes in PML bodies in response to HIV-1 infection. Experiments with PML-null target cells indicated that PML has no effect on HIV-1 infectivity and is dispensable for the stimulatory effect of As(2)O(3). As(2)O(3) caused cell death in uninfected cells at the same concentrations which stimulate HIV-1 replication. Among four additional apoptosis-inducing agents, a boost in HIV-1 infectivity was observed only with carbonyl cyanide m-chlorophenylhydrazone, a compound which, like As(2)O(3), disrupts the mitochondrial transmembrane potential. In summary, As(2)O(3) stimulates retroviral reverse transcription, perhaps via effects on mitochondria, and provides a useful tool for characterizing Ref1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12584341      PMCID: PMC149754          DOI: 10.1128/jvi.77.5.3167-3180.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  Bcl-2 inhibits apoptosis induced by mitochondrial uncoupling but does not prevent mitochondrial transmembrane depolarization.

Authors:  J S Armstrong; K K Steinauer; J French; P L Killoran; J Walleczek; J Kochanski; S J Knox
Journal:  Exp Cell Res       Date:  2001-01-15       Impact factor: 3.905

2.  Ubiquitin is part of the retrovirus budding machinery.

Authors:  A Patnaik; V Chau; J W Wills
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

3.  Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1.

Authors:  O Schwartz; V Maréchal; B Friguet; F Arenzana-Seisdedos; J M Heard
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA.

Authors:  P Wei; M E Garber; S M Fang; W H Fischer; K A Jones
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

5.  Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo.

Authors:  R Zufferey; D Nagy; R J Mandel; L Naldini; D Trono
Journal:  Nat Biotechnol       Date:  1997-09       Impact factor: 54.908

6.  Mouse-human heterokaryons support efficient human immunodeficiency virus type 1 assembly.

Authors:  R Mariani; B A Rasala; G Rutter; K Wiegers; S M Brandt; H G Kräusslich; N R Landau
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

7.  Role of PML in cell growth and the retinoic acid pathway.

Authors:  Z G Wang; L Delva; M Gaboli; R Rivi; M Giorgio; C Cordon-Cardo; F Grosveld; P P Pandolfi
Journal:  Science       Date:  1998-03-06       Impact factor: 47.728

8.  Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies.

Authors:  A L Adamson; S Kenney
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

9.  Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3.

Authors:  X H Jiang; B C Wong; S T Yuen; S H Jiang; C H Cho; K C Lai; M C Lin; H F Kung; S K Lam; B Chun-Yu Wong
Journal:  Int J Cancer       Date:  2001-01-15       Impact factor: 7.396

10.  Distinct mechanisms trigger apoptosis in human immunodeficiency virus type 1-infected and in uninfected bystander T lymphocytes.

Authors:  G Herbein; C Van Lint; J L Lovett; E Verdin
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

View more
  43 in total

1.  Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1.

Authors:  Cagan Gurer; Lionel Berthoux; Jeremy Luban
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Arsenic counteracts human immunodeficiency virus type 1 restriction by various TRIM5 orthologues in a cell type-dependent manner.

Authors:  Sarah Sebastian; Elena Sokolskaja; Jeremy Luban
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Retroviral restriction factors Fv1 and TRIM5alpha act independently and can compete for incoming virus before reverse transcription.

Authors:  Luca D Passerini; Zuzana Keckesova; Greg J Towers
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

4.  The role of lysine 186 in HIV-1 integrase multimerization.

Authors:  Lionel Berthoux; Sarah Sebastian; Mark A Muesing; Jeremy Luban
Journal:  Virology       Date:  2007-03-29       Impact factor: 3.616

5.  Cell context-dependent involvement of ATR in early stages of retroviral replication.

Authors:  Yi-Xin Yang; Vincent Guen; Jonathan Richard; Eric A Cohen; Lionel Berthoux
Journal:  Virology       Date:  2009-11-13       Impact factor: 3.616

6.  Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells.

Authors:  Lionel Berthoux; Sarah Sebastian; Elena Sokolskaja; Jeremy Luban
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

7.  Restriction of feline immunodeficiency virus by Ref1, Lv1, and primate TRIM5alpha proteins.

Authors:  Dyana T Saenz; Wulin Teo; John C Olsen; Eric M Poeschla
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

8.  The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities.

Authors:  Zuzana Keckesova; Laura M J Ylinen; Greg J Towers
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

9.  TRIM5alpha and TRIMCyp form apparent hexamers and their multimeric state is not affected by exposure to restriction-sensitive viruses or by treatment with pharmacological inhibitors.

Authors:  Marie-Edith Nepveu-Traversy; Julie Bérubé; Lionel Berthoux
Journal:  Retrovirology       Date:  2009-11-03       Impact factor: 4.602

10.  Heterologous human immunodeficiency virus type 1 lentiviral vectors packaging a simian immunodeficiency virus-derived genome display a specific postentry transduction defect in dendritic cells.

Authors:  Caroline Goujon; Loraine Jarrosson-Wuilleme; Jeanine Bernaud; Dominique Rigal; Jean-Luc Darlix; Andrea Cimarelli
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.